Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ARQ-252

Small molecule · developed by Arcutis Biotherapeutics

Phase 2 Most advanced trial (none active)
ARQT Developer
2 Registered trials

What is ARQ-252?

ARQ-252 is a drug studied in chronic hand eczema and vitiligo.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Dermatology
Developer
Arcutis Biotherapeutics, Inc. (ARQT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04811131 Phase 2 Vitiligo Terminated ARQT
NCT04378569 Phase 1/2 Chronic Hand Eczema Completed ARQT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Hand EczemaVitiligo

More from Arcutis Biotherapeutics

ARQ-154 Phase 2 ARQ-234 Phase 1

Follow ARQT, the company behind ARQ-252

See ARQT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARQT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.